Ribociclib Combo May Provide Benefit to Certain Breast Cancer Subtypes
Ribociclib (Kisqali) and endocrine therapy, compared with combination chemotherapy, demonstrated a trend towards a progression-free survival (PFS) benefit in patients with luminal B/HER2E intrinsic subtypes of breast cancer, according to a subgroup …